PARP1 and Alzheimer disease: In order to study the neuroprotective and therapeutic potential of PARP-1 functional inhibition in vivo, we evaluated the climbing ability of transgenic AD flies expressing the human Aβ42 peptide under the control of the heterologous upstream activation sequence (UAS) yeast sequences.